45 minutes
FDA approval used to mean access - but that's no longer the case. More insurers are restricting access to new drugs, all at the expense of patients, using the argument that they do not bring enough value to the healthcare system. But what does value really mean? Experts in pricing and market access offer thoughts on how we might solve the value equation to improve patient access while continuing to reward innovation.


Erin Mistry - Senior Managing Director, Head of Value, Access & HEOR, Syneos Health
Mike Bonney - Executive Chair, Kaleido Biosciences
Tamar Thompson - Executive Director, State Government Affairs & Federal Payment, Bristol-Myers Squibb
Name Audience
Conference Wide